---
title: "Defining estimand for win ratio"
subtitle: "How to separate true effect from censoring"
css: wr_style.css
csl: apa.csl
author:
  name: Lu Mao
  affiliations: 
    - name: Department of Biostatistics & Medical Informatics
    - University of Wisconsin-Madison
    - May 19, 2025
    - Main paper - [https://doi.org/10.1177/17407745241259356](https://doi.org/10.1177/17407745241259356)
  email: lmao@biostat.wisc.edu
format: 
  revealjs:
    theme: serif
    auto-stretch: false
    # incremental: true   
editor: visual
include-in-header:
  - text: |
      <style type="text/css">
      ul li ul li {
        font-size: 0.80em;
      }
      </style>
bibliography: references.bib
# title-slide-attributes: 
#   data-background-image: jsm_logo1.png
#   data-background-size: 18%
#   data-background-position: 50% 2%
---

## Outline

-   **Background**

-   **Censoring's impact on estimand**

    -   Time frame of comparison

-   **Two approaches to clarity**

    -   **Nonparametric**: fix the time frame
    -   **Semiparametric**: posit a time-constant feature

-   **Summary and discussion**

$$
\def\a{{(a)}}
\def\b{{(1-a)}}
\def\t{{(1)}}
\def\c{{(0)}}
\def\d{{\rm d}}
\def\T{{\rm T}}
$$

# Introduction

## Composite Endpoint

-   **Traditional composite endpoint (TCE)**
    -   **Time to first event**
        -   Major adverse cardiac event (MACE): death, heart failure, myocardio-infarction, stroke, etc.
    -   **Limitations**:
        -   Lack of clinical priority
        -   Statistical inefficiency (waste of data)
-   **Hierarchical composite endpoint (HCE)**
    -   **Example**: Death \> nonfatal MACE \> six-minute walk test (6MWT)/NYHA class

## Win Ratio: Basics

-   **A common approach to HCE**
    -   **Proposed and popularized** by @pocock2012
    -   **Treatment vs control**: generalized pairwise comparisons
    -   **Win-loss**: sequential comparison on components
        -   Longer survival \> fewer/later nonfatal MACE \> better 6MWT/NYHA score
    -   **Effect size**: WR $=$ wins / losses
-   **Alternative metrics**
    -   **Proportion in favor** (net benefit): PIF $=$ wins $-$ losses
    -   **Win odds**: WO $=$ (wins $+$ $2^{-1}$ties) / (losses $+$ $2^{-1}$ties)

## Win Ratio: Gaining Popularity

-   More trials are using it...

![](images/intro_Ntrial_title.png){fig-align="center" width="100%"}

# Estimand vs Censoring

## An Important Caveat

-   **WR's estimand depends on censoring ...**

    -   @Luo2015, @Bebu2016, @oakes2016, @Mao2019, @Dong2020a, @li2024, etc.

-   **What is an estimand?**

    -   Population-level quantity to be estimated
        -   Population-mean difference, (true) risk ratio, etc.
    -   Specifies how treatment effect is measured
    -   **ICH E9 (R1) addendum**: estimand construction one of the "*central questions for drug development and licensing*" [@ich2020]

## Time Frame of Comparison

-   **Cause of dependency on censoring**
    -   Censoring $\to$ time frame of comparison $\to$ magnitude of win/loss probabilities
-   **Example**
    -   **Pair 1**: one patient censored at year 1, the other $>1$ year
        -   Compared over $[0, 1]$ year
    -   **Pair 2**: neither patient censored until year 5
        -   Compared over $> [0, 5]$ years
        -   More events $\to$ fewer ties $\to$ higher win/loss proportions
        -   Prioritized components more likely conclusive, harder to pass

## Win-Loss Changes with Time

-   **Illustration**
    -   Win-loss status, and deciding component, changes with time ![](images/exmp.png){fig-align="center" width="85%"}
    -   Longer follow-up ...
        -   **Parameters**: win/loss proportions $\uparrow$ (WR uncertain); tie proportion $\downarrow$
        -   **Relative contribution**: prioritized $\uparrow$; deprioritized $\downarrow$

## Trial-Dependent Estimand

-   **Actual estimand**
    -   Average WR mixing shorter-term with longer-term comparisons
    -   Weight set (haphazardly) by censoring distribution
        -   Staggered entry, random withdrawal $\to$ non-scientific
-   **Testing vs estimation**
    -   **Testing (qualitative)**: okay
        -   Valid under $H_0$, powerful if treatment *consistently* outperforms control over time
    -   **Estimation (quantitative)**: not okay
        -   Needs a generalizable target quantity (scientific estimand)
        -   Unaffected by length of trial, rates of patient accrual/loss to follow-up, etc.

# Two Approaches to Meaningful Estimand

## General Strategies

-   **Goal**: a meaningful, generalizable WR estimand
    -   Unaffected by censoring distribution
-   **Key strategy**
    -   Be *proactive* on time frame of comparison
-   **Approaches**
    -   Choose a fixed time (nonparametric)
    -   Model time trajectory with a constant parameter (semiparametric)

## Time Restriction - Univariate

-   **Outcome data**
    -   $D^\a$: survival time for a patient in group $a$ ($1$: treatment; $0$: control)
        -   $S^\a(t) = P(D^\a>t)$
-   **Time restriction: a familiar concept**
    -   *Five-year* survival rate of breast cancer patients
        -   Estimand: $S^\t(\tau) - S^\c(\tau)$
    -   *Five-year* average survival time
        -   Estimand: $E\{\min(D^\t, \tau)\} - E\{\min(D^\c, \tau)\}$
        -   Restricted mean survival time (RMST)
    -   **Restriction time** $\tau=5$ years (pre-specify)

## Time Restriction - WR

-   **Two-tiered composite**
    -   $D^\a$: survival time; $T^\a$: time to (first) nonfatal MACE
-   **Restricted win/loss probability**
    -   Image all patients followed up to $\tau$ \begin{align}\label{eq:wl_2comp}
        w_{a, 1-a}(\tau) &=  \underbrace{P\{D^\b < \min(D^\a, \tau)\}}_{\mbox{win on survival}}\\
        & +
         \underbrace{P\{\min(D^\t, D^\c) > \tau, T^\b < \min(T^\a, \tau)\}}_{\mbox{tie on survival, win on nonfatal event}}
        \end{align}
    -   **Restricted WR**: ${\rm WR}(\tau)=w_{1, 0}(\tau)/w_{0, 1}(\tau)$

## Time Restriction - Estimation

-   **General case**
    -   Formulate win/loss probability as function of time based on *uncensored* outcomes
    -   Pick restriction time $\tau$
-   **Estimation**: must handle censoring properly
    -   **Inverse probability censoring weighting** [IPCW, @Dong2020; @Dong2021]
        -   **R-package**: `WINS` [@WINS]
    -   **Multiple imputations** for data censored before $\tau$ [@wang2023; @wang2024]

## Time Restriction - A Variation

-   **Take time difference into account**
    -   $w_{a, 1-a}(\tau)$: win probability by $\tau$ $\to$ average win time by $\tau$
    -   Restricted mean time in favor: $w_{1, 0}(\tau) - w_{0, 1}(\tau)$ [@Mao2023]
        -   **R-package**: `rmt` [@rmt]
        -   **Colon cancer trial**: levamisole + fluorouracil ($n =$ 304) vs control ($n =$ 314)

```{r}
#| label: tbl-cars
#| tbl-cap: "Restricted mean times in favor of treatment in a colon cancer trial by Ï„ = 7.5 years."
library(tidyverse)
library(knitr)

tab1 <- tibble(
 " " = c("Death", "Recurrence", "Overall"),
  `Estimate (yrs)` = c(0.62, 0.35, 0.97),
  `95% CI (yrs)` =c("(0.20, 1.04)", "(0.21, 0.49)", "(0.47, 1.46)"),
  `P-value` = c("0.004", "<0.001", "<0.001")
)



kable(tab1, align = "lccr")
```

## Temporal Modeling

-   **Cox proportional hazards (PH) model**
    -   Time-varying hazard $\stackrel{\rm PH}{\longrightarrow}$ time-constant hazard ratio (global effect)
    -   Checking proportionality: score residuals
-   **A proportional win-fractions (PW) model**
    -   Time-varying win-loss probability $\stackrel{\rm PW}{\longrightarrow}$ time-constant win ratio (global effect) [@Mao2021; @Wang2022] \begin{equation}\label{eq:pw}
        \frac{w_{1, 0}(t)}{w_{0, 1}(t)} = \exp(\theta) \mbox{ for
        some $\theta$ and all } t
        \end{equation}
        -   $\exp(\hat\theta)$: standard or time-weighted WR statistic
        -   **R-package**: `WR` [@WR]

## Checking Proportionality

-   **Cumulative residuals**\
    $$\hat{\mbox{resid}}(t) = \mbox{(Observed wins by $t$)} - \mbox{(Model-based wins by $t$)}$$

![](images/res_p.png){fig-align="center" width="95%"}

## Covariate Adjustment

-   **HF-ACTION trial**

    -   **Exercise training** $(n=1051)$ vs **usual care** $(n=1054)$ \begin{equation}\label{eq:pw_cov}
        \frac{w_{z, z'}(t)}{w_{z', z}(t)} 
        = \exp\{\theta(a - a') + \beta^\T(x - x')\} \mbox{ for
         all } t
        \end{equation}
    -   **Covariates** $x$: sex, etiology, CPX, medical history, etc.

    ```{r}
    #| label: tbl-hf-action
    #| tbl-cap: "Multiple PW regression for death > hospitalization in HF-ACTION."
    #| tbl-colwidths: [40, 15, 30, 15]
      
    tab2 <- tibble(
      " " = c("Training v usual",  "Male vs female", "Ischemic vs non-ischemic",
              "CP exercise test (minute)", "Atrial fibrillation"),
      "Win ratio" = c(1.06,  0.72, 0.87, 1.11, 0.80),
      "95% CI" = c("(0.95, 1.19)",  "(0.63, 0.82)", "(0.76, 0.98)", "(1.09, 1.13)",
                   "(0.70, 0.92)"),
      "P-value" = c("0.275",  "<0.001", "0.027", "<0.001", "0.002")
    )

    kable(tab2, align = c("lccr"), full_width = TRUE)

    # Predictor & Win ratio & 95\% CI & P-value\\
    # \midrule
    # Training v usual & 1.06 & (0.95, 1.19)&0.275\\\noalign{\smallskip}
    # Age (10 yrs) & 1.02 & (0.97, 1.07) & 0.468\\
    # Male v female & 0.72 &(0.63, 0.82)&$<$0.001\\
    # Ischemic v no & 0.87 &(0.76, 0.98)&0.027\\
    # CPX (minute) & 1.11 &(1.09, 1.13)&$<$0.001\\
    # AF v no & 0.80 &(0.70, 0.92)&0.002\\
    # Diabetes v no & 0.98 &(0.87, 1.11)&0.726\\\bottomrule
    ```

# Conclusion

## Summary

-   **How to separate true effect from censoring**
    -   Make a conscious choice on time frame of comparison
        -   Fix it (nonparametric) or model it (semiparametric)
-   **Time restriction vs temporal modeling**
    -   **Restricted win-loss**: model-free estimand, less efficient ([`WINS`](https://CRAN.R-project.org/package=WINS), [`rmt`](https://CRAN.R-project.org/package=rmt))
    -   **PW regression**: may be more efficient *if proportionality (constant WR) holds* ([`WR`](https://CRAN.R-project.org/package=WR))
-   **Combine the two**
    -   IPCW + working model for locally efficient estimation?
    -   Nonparametric estimand but semiparametric inference

## Future Work

-   **Sample size estimation**
    -   **Standard tests**: @gasparyan2021, @mao2022, @yu2022, @wang2023a, etc.
    -   **Restricted WR**: ??
-   **Intercurrent event**
    -   Treatment non-response/toxicity/discontinuation [@ich2020]
    -   **Hypothetical**: win/lose had treatment continued $\to$ imputation?
    -   **Composite**: death \> *treatment failure* \> lesser events?
    -   **Principal strata**: win/lose among those who would not experience treatment failure if assigned to either group (identifiability)

## For More

-   **Main paper**

> Mao, L. (2024). Defining estimand for the win ratio: separate the true effect from censoring. *Clinical Trials*, 21, 584-594. <https://doi.org/10.1177/17407745241259356>

-   **Slides URL**: <https://lmaowisc.github.io/ce/win_ratio_estimand.html>

## Acknowledgments

-   **Funding**

    -   [R01HL149875](https://reporter.nih.gov/search/9aSu5u3xlE26GrjbF_4cBg/project-details/10734551) (11/2019 -- 7/2028)
    -   [DMS2015526](https://www.nsf.gov/awardsearch/showAward?AWD_ID=2015526) (7/2020 -- 6/2024) ![](images/funds.png){fig-align="center" width="70%"}

-   **Collaborators**

    -   [KyungMann Kim](https://biostat.wiscweb.wisc.edu/staff/kim-kyungmann/), [Tuo Wang](https://tuowang.rbind.io/), Gaohong Dong, Bo Huang, etc.

## References
